
Various embodiments of the invention are presented hereafter:

1) In one aspect, there is provided~~The present invention relates to~~ compounds of the formula (I),



(I)

wherein

W represents $-CH_2CH_2-$ or -CH=CH-;

Y represents a bond or a (C_1-C_4)alkandiyl group and $\mathbf{R^1}$ represents

- an aryl- or a heteroaryl-group, which groups are independently unsubstituted, mono-, di- or tri-substituted, wherein the substituents are independently selected from the group consisting of halogen, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_2)alkyl-carbonyl, (C_1-C_2)fluoroalkyl, (C_1-C_2)fluoroalkoxy, nitro, cyano and phenyl, wherein the phenyl is unsubstituted or mono-substituted with halogen; or
- benzo[*d*][1,3]dioxolyl; or
- aryloxy; or
- a cyclohexyl- or a cyclohexenyl-group, which groups are independently unsubstituted or mono-substituted with (C_1-C_4)alkyl; or
- (C_1-C_2)alkyl-carbonyl; or
- (C_1-C_4)alkoxy-carbonyl;

or **Y** represents together with $\mathbf{R^1}$ a (C_4-C_6)alkyl group or a amino-(C_4-C_6)alkyl group;

Z represents $-C(O)NR^3-*$ or $-CH_2NR^4C(O)-*$,
wherein the asterisks indicate the bond which is linked to R^2;

$\mathbf{R^2}$ represents

- (C_3-C_6)cycloalkyl, which is unsubstituted or mono-substituted with hydroxy, hydroxy-methyl, $R^5R^6N-CH_2-$, heterocyclyl-methyl or $-CONH_2$; or
- (C_1-C_6)alkyl, which is unsubstituted or mono-substituted with fluorine, trifluoromethyl, (C_1-C_4)alkylthio, (C_1-C_4)alkoxy-carbonyl, hydroxy, cyano, $-NR^5R^6$, –

R^{7} and **R**^{8} represent independently from each other hydrogen or methyl; or
R^{7} and **R**^{8} form, together with the nitrogen that carries them, a pyrrolidine or piperidine ring; and

R^{9} represents hydrogen or *tert*-butoxycarbonyl;

and to the salts (in particular pharmaceutically acceptable salts) of such compounds.

In another aspect, there is provided a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for use as medicament.


In yet another aspect, there is provided a pharmaceutical composition containing, as active principle, a compound of formula (I) as defined above or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

In still another aspect, there is provided the use of a compound of formula (I) as defined above, or of a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention or treatment of a disease selected from inflammatory diseases, obstructive airway diseases, allergic conditions, HIV-mediated retroviral infections, cardiovascular disorders, neuroinflammation, neurological disorders, pain, prion-mediated diseases and amyloid-mediated disorders; and for the modulation of immune responses.

For avoidance of any doubt, the term "**Z** represents -C(O)NR^{3}-*, wherein the asterisk indicates the bond which is linked to R^{2}" means that the residue R^{2} is linked to the nitrogen atom of the amide moiety.


The configuration of compounds of formula (I) according to embodiment 1) is such that the substituent R^{1}-Y-NH-C(O)- is in relative proximity to the group **W** (*endo*-position), whereas the substituent R^{2}-Z- is in relative proximity to the cyclopropyl-moiety (*exo*-position).

Formula I comprises compounds of formula I_{St1} and of formula I_{St2} and mixtures thereof.



(I_{St1})

(4*S*,5*R*,6*R*,7*R*)



(I_{St2})

(4*R*,5*S*,6*S*,7*S*)

For avoidance of any doubt, compounds of formula (I) are denominated in analogy to the following examples:

a mixture of enantiomers of structure